GLP‑1 weight‑loss drugs such as Ozempic transform markets, health outcomes and patient experiences worldwide

GLP‑1 medicines—including semaglutide‑based Ozempic, Wegovy and oral Rybelsus, as well as tirzepatide‑based Mounjaro—have sparked a multi‑billion‑dollar market surge. In Brazil, sales of these “fat‑burning pens” grew from R$ 1.8 billion in 2021 to about R$ 10 billion in 2025, with Ozempic alone generating roughly R$ 11.3 billion.

A U.S. study of 242 women using GLP‑1 drugs found they were 27 percentage points more likely to gain employment and 29 points more likely to form new partnerships, yet overall life‑satisfaction did not improve. The research also highlighted unequal access, with users earning on average $83,000 versus $60,000 for non‑users.

Separate reports from Italy and Spain note that rapid weight loss can produce a distinctive “Ozempic face” – facial hollowness, sagging skin and premature‑looking wrinkles – prompting increased demand for facial‑lifting procedures.

A cohort analysis of over 44 000 diabetes patients treated with semaglutide or tirzepatide found no clear cognitive‑decline benefit, echoing earlier phase‑3 trials that failed to slow Alzheimer’s progression.

Finally, a phase‑3 trial of the oral drug orforglipron (Eli Lilly) showed greater HbA1c reduction (‑1.8 % vs ‑1.5 % for oral semaglutide) and modestly more weight loss, but with higher gastrointestinal side‑effects and a 10 % discontinuation rate.